Brief: Galderma - New Published Data Confirms Nemluvio Can Rapidly Relieve Itch And Improve Sleep In As Early As Two Days In Both Atopic Dermatitis And Prurigo Nodularis
Dec 17 (Reuters) - GALDERMA GROUP AG GALD.S: NEW PUBLISHED DATA CONFIRMS NEMLUVIO® (NEMOLIZUMAB) CAN RAPIDLY RELIEVE ITCH AND IMPROVE SLEEP IN AS EARLY AS TWO DAYS IN BOTH ATOPIC DERMATITIS AND PRURIGO NODULARIS Source text: ID:nBw44PSLMa Further company coverage: GALD.S (Gdansk Newsroom) ((gdansk.newsroom@thomsonreuters.com; +48 58 7696600;))
Recent news on Galderma AG
See all newsBrief: Galderma Receives U.S. FDA Approval For Differin Epiduo Acne Gel Prescription-To-Otc Switch
Bayer down after 'mixed reception' at U.S Supreme Court
Europe Research Roundup: Asta Energy Solutions, Dassault Systemes, Nokia
Swiss stocks - Factors to watch on April 24
Skincare company Galderma posts 25.5% sales leap, driven by US market (updated)